Answers are grounded in this paper and cite their sources.
Observational study shows trends in drug approvals for various conditions, indicating a focus on anticancer treatments.
There has been a steady rate of introduction of new drugs by CDER over the last two decades. Expedited approval of anticancer and biologics is seen as recent trend in drug development. Relatively, slow progress in approval of drugs for neurological disorders (depression, psychosis, multiple sclerosis, etc.) and lifestyle diseases like obesity, atherosclerosis, diabetes, etc., were seen. These findings reflect more emphasis being laid down in research for anticancer drugs and biologics.
No takes yet. Share an insight, caveat, or question.
Kalra et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: